United States - English - NLM (National Library of Medicine)

apace packaging, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) -  uroav-81 tablets is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uroav-81 tablets is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

United States - English - NLM (National Library of Medicine)

key therapeutics - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), benzoic acid (unii: 8skn0b0mim) (benzoic acid - unii:8skn0b0mim), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), hyoscyamine (unii: px44xo846x) (hyoscyamine - unii:px44xo846x) - u r i s e d™ is indicated for the relief of discomfort of the lower urinary tract caused by hypermotility resulting from inflammation or diagnostic procedures and in the treatment of cystitis, urethritis, and trigonitis when caused by organisms which maintain or produce an acid urine and are susceptible to formaldehyde. glaucoma, urinary bladder neck obstruction, pyloric or duodenal obstruction, or cardiospasm. hypersensitivity to any of the ingredients. a dependence on the use of u r i s e d™ has not been reported and due to the nature of its ingredients, abuse of u r i s e d™ is not expected.

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - ustell © capsules are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of ustell © capsules has not been reported and due to the nature of its ingredients, abuse of ustell © capsules is not expected.

United States - English - NLM (National Library of Medicine)

mission pharmacal company - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - uribel © capsules indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of uribel © capsules has not been reported and due to the nature of its ingredients, abuse of uribel © capsules is not expected.

United States - English - NLM (National Library of Medicine)

seachem laboratories inc. - glutaral (unii: t3c89m417n) (glutaral - unii:t3c89m417n), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh) -

United States - English - NLM (National Library of Medicine)

biocomp pharma - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - phosphasal ® tablets are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of phosphasal ® tablets has not been reported and due to the nature of its ingredients, abuse of

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - 61248 - perioperative methylene blue stain - the device is intended to be used in surgery for the marking of tissues and surgical findings and to test the tightness of urinary tract sutures and colorectal sutures.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - 61248 - perioperative methylene blue stain - the device is intended to be used for the marking of tissues for surgical findings, for intra-operative lymphatic mapping and to test the tightness of urinary tract sutures and colorectal sutures

United States - English - NLM (National Library of Medicine)

scite pharma, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - urimar-t™ is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. urimar-t™ is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urimar-t™ has not been reported and due to the nature of its ingredients, abuse of urimar t™ is not expected.

United States - English - NLM (National Library of Medicine)

a.g. marin pharmaceutical - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - uretron d/s tablets are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of uretron d/s tablets has not been reported and due to the nature of its ingredients, abuse of uretron d/s tablets is not expected.